- RSI is at a high level of 74. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 1.1. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stocks of start-ups wielding tools like Crispr-Cas9 that allow companies to edit DNA and attack genetic diseases and cancer are suddenly hot. But the science is moving with incredible speed and the competition is rising.
The company is exploring a technology called base editing to potentially develop a new class of precision genetic medicines, according to its website. In this daily Japanese candlestick chart of BEAM, below, we can see a limited base around the $20 area followed by three plus months of soaring prices. The slopes of the 50-day and 200-day moving averages are positive, but these are lagging indicators.
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Kate Walsh, president and chief executive officer of the Boston Medical Center (BMC) health system, has joined the company’s board of directors. BMC is a private, not-for-profit, academic medical center with a community-based focus and is the primary teaching affiliate of Boston University School of Me...
Intellia Therapeutics offered an update Thursday for its gene-editing programs, helping boost genetics stocks Crispr Therapeutics, Editas Medicine, Fate Therapeutics and Beam Therapeutics.
Scientists report that a novel gene-editing technology was able to correct the genetic mutation that causes progeria in lab mice and spare them its effects.
Investors need to pay close attention to Beam Therapeutics (BEAM) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 11:40 a.m. ET.The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the...
We have highlighted the best ETF of December and its best performing stocks.